Protection of human gastric mucosa against aspirinðenteric coating or dose reduction?
|
|
- Judith Dorsey
- 5 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 1999; 13: 187±193. Protection of human gastric mucosa against aspirinðenteric coating or dose reduction? A. T. COLE*, N. HUDSON*, L. C. W. LIEW*, F. E. MURRAY*, C. J. HAWKEY* & S. HEPTINSTALL *Division of Gastroenterology, Division of Cardiovascular Medicine, University Hospital, Nottingham, UK Accepted for publication 23 October 1998 SUMMARY Background: Aspirin is widely used for cardiovascular prophylaxis. Aim: To compare the effectiveness of two widely-used strategiesðdose reduction and enteric coatingðfor the minimization of gastric mucosal injury or toxicity. Methods: Twelve healthy volunteers were studied. On four separate occasions each received, under blinded conditions, ve daily doses of plain aspirin 300 mg, plain aspirin 75 mg, enteric-coated aspirin 300 mg or placebo. Ex vivo prostaglandin E 2 synthesis was stimulated by the vortex mixing of gastric mucosal biopsies in Tris saline and measured by radioimmunoassay. Mucosal injury was quanti ed both by counting erosions and with a visual analogue scale. Results: All three preparations reduced prostaglandin E 2 synthesis by day ve, by (median) 84% for plain aspirin 300 mg, by 80% for enteric coated aspirin 300 mg and by 63% for plain aspirin 75 mg. There was little mucosal injury prior to the start of each dose and period and no signi cant change with placebo. Plain aspirin caused a dose-dependent mucosal injury, with two (median, IQR 0±7) gastric erosions after ve days of plain aspirin 75 mg, and 18 (2±26) after ve days of plain aspirin 300 mg. With enteric-coated aspirin 300 mg there were 0 (0±1) gastric erosions (P ˆ compared to plain aspirin 300 mg P ˆ 0.11, compared to plain aspirin 75 mg). Conclusion: Enteric coated aspirin reduces acute gastric mucosal injury to placebo levels, despite its inhibition of prostaglandin synthesis. Enteric coating is an appropriate strategy for the prevention of gastric mucosal damage induced by low-dose aspirin, which warrants systematic clinical evaluation. INTRODUCTION Aspirin is increasingly used for cardiovascular prophylaxis in a daily dose range of between 75 and 300 mg daily. 1 Along with the bene ts of low dose aspirin there are hazards. Aspirin predisposes to both peptic ulceration, ulcer bleeding, anaemia and the need for transfusion, 1, 2 even at low doses. 3 Strategies for protection of the gastric mucosa include using the lowest effective dose of aspirin or using an enteric coated preparation. The enteric coating of Correspondence to: Prof. C. J. Hawkey, Division of Gastroenterology, University Hospital, Nottingham, NG7 2UH, UK. cj.hawkey@nottingham.ac.uk aspirin, when it is given at higher doses, is known to protect the gastroduodenal mucosa. 4, 5 However, it is not clear from current studies whether daily doses of aspirin lower than 300 mg are associated with fewer gastrointestinal adverse effects compared with conventionally formulated and enteric coated aspirin. Ideally, the drug regimen should provide an effective inhibition of platelet function with minimum gastric damage. We therefore carried out an investigation in which we compared the effects of once daily doses of plain aspirin 300 mg, plain aspirin 75 mg, enteric coated (EC) aspirin 300 mg and placebo on gastric mucosal prostaglandin (PG) E 2 synthesis and acute gastroduodenal damage. Ó 1999 Blackwell Science Ltd 187
2 188 A. T. COLE et al. METHODS Study design The study was an investigator blinded, placebo controlled study comparing plain aspirin 300 mg daily (Wallace Laboratories, UK) plain aspirin 75 mg daily (Evans, Horsham, UK), EC aspirin 300 mg daily (Nuseals, Eli Lilly, UK), and placebo. The order in which subjects received the different treatment regimens was randomized in blocks of four by the Latin square design. Each treatment period was for ve daily doses of medication taken at hours. There was a washout period of 16 days between treatment periods. Previous studies have shown that acute aspirin induced lesions and changes in prostaglandin synthesis resolve within 48 h. Subjects We studied 12 healthy volunteers, seven male, ve female, age range 20±32 years. All subjects considered for entry into the study had a screening endoscopy and were excluded if they had any erosions or ulcers. The study was approved by the University of Nottingham Ethics Committee and all volunteers gave written informed consent. Endoscopy Subjects underwent unsedated endoscopy, using an Olympus XP10 endoscope. Mucosal injury was quanti- ed by counting the number of erosions in the oesophagus, the stomach as a whole, in the body, antrum separately and in the duodenal bulb. 6 An erosion was de ned as a break in the mucosa 3 mm or less in diameter, less than 1 mm deep. Larger or deeper erosions were classi ed as ulcers. Mucosal injury in the gastric body, antrum and duodenum was also quanti- ed on a 10-cm visual analogue scale as previously described. 5 Prostaglandin E 2 synthesis Two pairs of mucosal biopsy specimens were taken, at 50 cm from the teeth from a standardized point on the greater curve. Each pair was transferred to 1 ml of Tris saline (0.15 M, ph 7.4) in separate polypropylene Eppendorf vials at room temperature and washed twice by vortex mixing for 6 s on a bench mixer (Whirlimixer, Fisons plc, UK). Three hundred microlitres of fresh Tris saline were then added and the tubes were vortexed for 1 min, before centrifugation for 10 s. Supernatants were removed and stored at )40 C until radioimmunoassay. 6, 7 Statistics The primary gastric end-points, stated prior to the start of the study, were changes in ex vivo prostaglandin (PGE 2 ) synthesis and the total number of gastric erosions. Overall differences at day 5 were examined by Friedman two-way analysis of variance. Comparisons between the effect of individual drugs were analysed using the Wilcoxon rank sign test. Data are presented as median and interquartile range. All tests were two-tailed and a P-value of 0.05 was taken as signi cant. RESULTS Prostaglandin E 2 synthesis Analysis of variance showed no signi cant difference in baseline values before each of the four treatment periods. However, changes due to aspirin were highly signi cant and there were signi cant differences between the different preparations of aspirin (P ˆ 0.003). As shown in Figure 1a, placebo did not signi cantly affect PGE 2 synthesis. With plain 300 mg aspirin there was an 84.5% (62.0±91.1%) reduction in PGE 2 synthesis, from 94.5 pg/mg (median, IQR: 50.5±183.1 pg/mg) before treatment to 11.8 (7.8±35.7) pg/mg on day 5 (P ˆ compared with placebo). Plain aspirin 300 mg signi cantly inhibited prostaglandin synthesis within 90 min of the rst dose, and there was no further depression by day 5 (Figure 1b). Plain aspirin 75 mg reduced PGE 2 synthesis by 63.4% (41.8±90.7%) from (53.8±293.1) pg/mg before treatment to 26.5 (13.8±108.4) pg/mg on day 5 (P ˆ compared to placebo). This was signi cantly less than the inhibition seen with plain aspirin 300 mg (P ˆ compared to plain aspirin 300 mg). Plain aspirin 75 mg also signi cantly inhibited PGE 2 synthesis after one dose (P ˆ 0.023), with no further depression by day 5 (Figure 1c). EC aspirin 300 mg reduced PGE 2 synthesis by 79.8% (48.3±92.4%) from (25.6 ±211.5) pg/ mg before treatment, to 14.9 (10.2±38.1) pg/mg by day 5 (P ˆ 0.004), although no inhibition was evident after
3 ASPIRIN AND THE GASTRIC MUCOSA 189 Figure 1. Gastric mucosal prostaglandin E 2. Individual data are shown for each treatment (panels a±d) and for each time point (day 0: pre-treatment) day 1 ˆ 90 min post rst dose, day 5 ˆ after ve daily doses: paired data are shown connected by lines. Vertical axis ˆ pg/mg tissue wet weight. the rst dose. Mucosal PGE 2 levels after 5 days of EC aspirin tended to be lower than those with aspirin 75 mg (P ˆ 0.117) and were not signi cantly different from plain aspirin 300 mg. Mucosal injury Erosions. At baseline there were 0(0±0) erosions Figure 2). Analysis of variance showed signi cant overall differences in total gastric erosions between aspirin preparations during treatment (P ˆ 0.01). There were 18 (2±26) erosions with plain aspirin 300 mg (P ˆ compared to placebo) and 2(0±7) with plain aspirin 75 mg (P ˆ compared to placebo). With EC aspirin 300 mg there were 0(0±1) erosions at day 5. This was not signi cantly different from placebo values and signi cantly less than plain aspirin 300 mg (P ˆ 0.003). There was a trend to fewer erosions with enteric coated aspirin 300 mg compared to plain aspirin 75 mg, although this did not achieve statistical signi cance (P ˆ 0.11). A similar pattern of differences between aspirin treatments was seen when erosions in the gastric body and antrum were counted individually. There was little duodenal injury and no signi cant differences between the groups in this respect. After 5 days treatment there were 0(0±1) duodenal erosions with plain aspirin 300 mg, 0(0±0.5) with plain aspirin 75 mg, 0(0±1) with enteric coated aspirin 300 mg and 0(0±10) on placebo. In one subject on plain aspirin 75 mg there were 16 duodenal erosions. No ulcers were seen on any treatment. Visual analogue scores. Quanti cation of injury using visual analogue scores gave similar ndings to the erosion counts (Table 1). At baseline, the median scores were all 0. After 5 days of treatment with aspirin 300 mg the score was 16 (0.5±40.3) mm for body
4 190 A. T. COLE et al. Figure 2. Gastric erosion Individual data are shown for each treatment (panels a±d) and for each time point (day 0 ˆ pretreatment) day 1±90 min post rst dose, day 5 ˆ after ve daily doses: paired data are shown connected by lines. Vertical axis ˆ number of gastric erosions. (P ˆ compared with placebo) and 14.5 (5.3± 33.8) mm for antrum (P ˆ 0.01 compared with placebo). With plain aspirin 75 mg the visual analogue scores were 3.5(0±16) mm for body (P ˆ 0.21 compared with placebo, P ˆ compared to plain aspirin 300 mg) and 6(0±19.5) for antrum (P ˆ compared with placebo, P ˆ 24 compared to plain aspirin 300 mg). Injury scores with EC aspirin 300 mg were 0(0±1.5) for body (P ˆ 0.05 compared with plain aspirin 75 mg, P ˆ compared with plain aspirin 300 mg) and 1(0±9.3) for antrum (P ˆ 0.31 compared with placebo, P ˆ 0.20 compared with plain aspirin 75 mg, P ˆ compared with plain aspirin 300 mg). Safety and tolerability Few new symptoms were recorded during the study. Two subjects reported abdominal pain that they specifically related to air insuf ation at endoscopy. Mild epigastric pain was recorded in one subject following a single dose of placebo, in one subject following a single dose of plain aspirin 300 mg, and in one subject during treatment with plain aspirin 75 mg. Severe epigastric pain was recorded in the one subject following a single dose of EC aspirin 300 mg. None of these subjects had recurrent pain with subsequent doses of the same preparations, required any drug therapy or withdrew from the study. DISCUSSION In this study the effects of three aspirin preparations on gastric mucosal prostaglandin synthesis and gastroduodenal mucosal injury were compared directly. Each of the three formulations of aspirin signi cantly inhibited ex vivo gastric mucosal PGE 2 synthesis, although the plain aspirin 75 mg preparation was signi cantly less effective than the 300 mg preparations. There was a slower onset of action for EC aspirin. However, there
5 ASPIRIN AND THE GASTRIC MUCOSA 191 Table 1. Erosions: visual analogue scores Plain aspirin EC aspirin Plain aspirin Placebo 75 mg 300 mg 300 mg Body Day 0 0(0±0) O(0) 0(0±1) 0(0±0.8) Day 1 6.5(0±11) 0(0±19.8) 0.5(0±7) 13.5(0.3±7.3) Day 5 1.5(0±12.5) 3.5(0±16) 0(0±1.5) 16(0.5±40.3) Antrum Day 0 0(0±0.8) 0(0±0.75) 0(0±0) 0(0±1) Day 1 0(0±0.8) 0(0±11.5) 0(0±0.8) 11.5(0±18) Day 5 0.5(0±4.2) 6(0±19.5) 1(0±9.3) 14.5(5.3±33.8) Duodenum Day 0 0(0±0) 0(0±0) 0(0±0) 0(0±0) Day 1 0(0±0) 0(0±0) 0(0±0.75) 0(0±1.8) Day 5 0(0±0) 0(0±2.8) 0(0±0) 3(0±8.5) All data are given as median and interquartile ranges of the visual analogue score in mm (100 mm maximum). were marked differences in the amount of mucosal injury seen with the different formulations of aspirin. Plain aspirin caused signi cant dose-related increases in mucosal injury whether measured by mucosal lesion counts, or the visual analogue score. Elsewhere we have reported that EC aspirin was as effective as the same dose of plain aspirin in its effects on a variety of measures of platelet function. 8 We have previously reported a comparison of higher doses of both aspirin 2.4 g daily and 300 mg daily between plain and enteric coated preparations and found similar results to those presented here. Enteric coating gave almost complete protection against gastric erosion formation. Other authors have also demonstrated protection with higher doses of enteric coated aspirin. 4 Our data show that EC aspirin 300 mg caused the least gastric injury of the three preparations tested. This occurred despite reductions in the ex vivo synthesis of PGE 2 to levels which were comparable to those seen with plain aspirin and bio-equivalence of their effects on platelet function. 8 Reduced mucosal injury in the face of reduced prostaglandin synthesis supports the idea that there is a topical component to the injury caused by plain aspirin and that abrogation of this topical injury is the basis of the protection associated with enteric coating of aspirin. Topical injury with aspirin may arise by a number of mechanisms. Aspirin accumulates in the gastric mucosa when absorbed from an acidic milieu and may interfere with metabolic processes which include oxidative phosphorylation. 9 Aspirin also associates with hydrophobic phospholipids in the gastric mucus and surface mucosal layer, so impairing the function of the mucus and mucosal barriers. 10 Plain aspirin dissolves in the stomach and may in part affect mucosal prostaglandin synthesis as a result of luminal delivery. By contrast, the inhibition of prostaglandin synthesis by enteric coated aspirin is likely to have occurred because of systemic delivery of aspirin to the gastric mucosa. Lower doses of aspirin have been shown to acetylate platelet cyclo-oxygenase in the pre-systemic circulation and before elimination by rst pass metabolism by the liver. It is therefore possible that enteric coated aspirin in very low doses might achieve both the bene ts of aspirin on platelets without any exposure at all of the gastric mucosa to aspirin, and it would seem that this would be worth investigating. Although our study has covered short-term changes in young healthy volunteers, it is likely that similar relationships would be seen for longer ingestion by older patients. Acute studies of protective strategies have shown that normal doses of H 2 antagonists do not prevent gastric erosions, 11, 12 whilst higher doses, 12 proton pump inhibitors 13 and misoprostol 14, 15 do. These results have been replicated in clinical studies of patients with arthritis taking NSAIDs on a long-term basis. 15±24 Moreover, when old and young subjects have been compared, there were no differences in acute mucosal injury. 25 Epidemiological studies have found that use of enteric coating or non-oral routes of administration are still associated with an increased tendency to upper gastrointestinal bleeding. 26 However,
6 192 A. T. COLE et al. these results may be confounded by dose and multiple drug use and do not apply speci cally to aspirin. Our data con rm that the enteric coating of aspirin is one way of protecting the stomach from aspirin, while at the same time allowing the complete suppression of eicosanoid-dependent platelet function. 7 Other prophylactic strategies to protect the stomach and duodenum against the ulcerogenic action of nonsteroidal antiin ammatory drugs may be used, including the use of ulcer healing drugs 24 and mucosal protection agents such as misoprostol. 15±24 In the future, inhibitors of the inducible cyclo-oxygenase (COX-2) pathway 8, 25 or 26, 27 nitric oxide donating NSAIDs may prove safer than existing agents. However, COX-2 inhibitors do not affect platelet function and will have no utility as cardiovascular prophylaxis. Strategies which employ co-prescription are not proven by long-term studies for aspirin users. Enteric coating of aspirin or very low dose preparations are established effective ways of minimising mucosal injury due to aspirin whilst still achieving an effective inhibition of platelet function. Our data suggest that EC 300 mg had a small advantage over 75 mg plain aspirin in this respect, and could prove preferable for long-term use. ACKNOWLEDGEMENT We thank Eli Lilly for nancial support. REFERENCES 1 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Eng J Med 1989; 321: 131±5. 2 Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219±26. 3 Slattery J, Warlow CP, Shorrock CJ, Langman MJS. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirinðanalysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 337(4): 509±11. 4 Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin and enteric-coated aspirin on gastric and duodenal mucosa. N Eng J Med 1980; 330: 136±8. 5 Hawthorne AB, Hurst SM, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating of aspirin and relation to prostaglandin synthesis. Br J Clin Pharmacol 1992; 32: 77±83. 6 Hawkey CJ. Synthesis of prostaglandin E 2 thromboxane B 2 and prostaglandin catabolism in gastritis and gastric ulcer. Gut 1970; 27: 148±51. 7 May JA, Heptinstall S, Cole AT, Hawkey CJ. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. Thrombosis Res 1997; 88: 183±92. 8 Wallace JL, Cirino G. The development of gastrointestinalsparing nonsteroidal anti-in ammatory drugs. Trends Pharmacol Sci 1994; 15: Sato Y, Asaka M, Takeda H, Ohtaki T, Miyazaki T. The mechanisms of aspirin induced gastric mucosal injury. J Clin Gastroenterol 1993; 17: S2±S4. 10 Lichtenberger LM, Wang Z-M, Romero JJ, et al. Non-steroidal anti-in ammatory drugs (NSAIDs) associate with Zwitterionic phospholipids: Insight into the mechanisms and reversal of NSAID-induced gastrointestinal injury. Nature Med 1995; 1: 154±8. 11 Cole AT, Brundell S, Hudson N, Hawthorne AB, Mahida YR, Hawkey CJ. Ranitidine: differential effects on gastric bleeding and mucosal damage induced by aspirin. Aliment Pharmacol Ther 1992; 6: 707± Daneshmend TK, Pritchard PH, Bhaskar NK, Millns P, Hawkey CJ. Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine. Gastroenterology 1989; 97: 944±9. 13 Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin-induced gastric mucosal injury in man. Gut 1990; 31: 514± Bardham KD, Bjarson I, Scott DL, et al. The prevention and healing of acute nonsteroidal anti-in ammatory drug associated gastroduodenal mucosal damage by misoprostal. Br J Rheumatol 1993; 32: 990±5. 15 Walt RP. Misoprostol for the treatment of peptic ulcer and anti-in ammatory drug-induced gastroduodenal ulceration. N Eng J Med 1992; 327: 1575± Koch M, Capurso L, Dezi A, Ferrario F, Scarpignato C. Prevention of NSAID-induced gastroduodenal mucosal injuryðmetaanalysis of clinical trials with misoprostol and H-2 receptor antagonists. Dig Dis 1995; 13: 62± Graham DY, Smith JL, Holmes GI, Davies RO. Relationship between non-steroidal anti-in ammatory effect and gastric mucosal injury. Gastroenterolgoy 1983; 84: Graham DY, Agrawal NM, Roth SH. Prevention of NSAIDÐinduced gastric ulcer with misoprostolðmulticenter double-blind, placebo-controlled trial. Lancet 1988; 2: 1277± Elliot SL, Yeomans ND, Buchanan RRC, Smallwood RA. Ef cacy of 12 months misoprostol as prophylaxis against NSAIDinduced gastric ulcersða placebo controlled trial. Scand J Rheumatol 1994; 23: 171±6. 20 Silverstein FE, Graham DY, Senior JR, et al. Misprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-in ammatory drugsða randomised double blind, placebo-controlled trial. Ann Internal Med 1995; 123: 241±9. 21 Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by
7 ASPIRIN AND THE GASTRIC MUCOSA 193 non-steroidal anti-in ammatory drugs. New Engl J Med 1996; 334: 1435±9. 22 Yeomans ND, Tulassay Z, Juhasz L, et al. for the ASTRONAUT Study Group. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non steroidal anti-in ammatory drugs. The ASTRONAUT Study New Engl J Med 1998; 338: 719± Hawkey CJ, Karrasch JA, Szczepanski L, et al. for the OMNIUM Study Group. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non steroidal anti-in ammatory drugs the OMNIUM study. New Engl J Med 1998; 228: 727± Hawkey CJ, Kahan A, Steinbruck K, et al., and the International MELISSA Study Group. Gastrointestinal tolerability of the COX-1 inhibitor, Meloxicam, in osteoarthritis patients: The meloxicam large scale international study safety assessment (MELISSA). Br J Rheumatology 1998; 338: 719± Donnelly MC, Hawkey CJ. COX-2 Inhibitors ± a new generation of safer NSAIDs. Ailment Pharmacol Therap 1997; 11: 227± Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-in ammatory drugs. Gastoenterology 1993; 105: 1078± 88.
Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?
Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,
More informationEnhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine
Br. J. clin. Pharmac. (1989), 28, 581-585 Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine G. K. KITCHINGMAN, P. J. PRICHARD, T. K. DANESHMEND,
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationIs ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?
ORIGINAL PAPER doi: 10.1111/j.1742-1241.2006.01147.x Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? N. D. YEOMANS, 1 *L-ESVEDBERG,
More informationThe long-term management of patients with bleeding duodenal ulcers
Aliment Pharmacol Ther (1997); 11: 505±510. The long-term management of patients with bleeding duodenal ulcers M. E. MCALINDON, J. S. W. TAYLOR & S. D. RYDER Department of Medicine, University Hospital,
More informationOmeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer
Aliment Pharmacol Ther 1998; 12: 355±360. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer G. BIANCHI PORRO, M. LAZZARONI, G. MANZIONNA & M. PETRILLO Gastrointestinal
More informationSurvey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly
Aliment Pharmacol Ther 1999; 13: 813±817. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly R. BOUTET, M. WILCOCK & I. MACKENZIE 1 Department of
More informationPhospholipid Association Reduces the Gastric Mucosal Toxicity of Aspirin in Human Subjects
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 94, No. 7, 1999 1999 by Am. Coll. of Gastroenterology ISSN 0002-9270/99/$20.00 Published by Elsevier Science Inc. PII S0002-9270(99)00267-1 Phospholipid Association
More informationOriginal Article. Abstract. Introduction
Original Article Frequency of NSAID Induced Peptic Ulcer Disease Saeed Hamid, Javed Yakoob, Wasim Jafri, Shanul Islam, Shahab Abid, Muhammad Islam Section of Gastroenterology, Department of Medicine, Aga
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationWhat is Bandolier? Balance benefits and harms
What is Bandolier? The first issue of Bandolier, an independent journal about evidence-based healthcare, written by Oxford scientists, (RAM AND HJM) was printed in February 1994. It has appeared monthly
More informationNSAID-Induced Gastrointestinal Damage
GASTROENTEROLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board
More informationProton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs
ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationPREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS
PREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS LANSOPRAZOLE FOR THE PREVENTION OF RECURRENCES OF ULCER COMPLICATIONS FROM LONG-TERM LOW-DOSE ASPIRIN USE KAM CHUEN LAI, M.R.C.P., SHIU KUM LAM, M.D., KENT
More informationEffective management of gastrointestinal PROCEEDINGS EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS *
EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS * David A. Peura, MD, FACP, FACG ABSTRACT *This article is based on a presentation given by Dr Peura at the PRI-MED
More informationThe cardioprotective benefits of ... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin. Byron Cryer, MD
... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin Byron Cryer, MD Abstract The cardioprotective benefits of aspirin support the use of low-dose regimens for primary and secondary prevention of
More informationGASTRODUODENAL damage can be seen on endoscopy
Vol. 334 No. 22 TO PREVENT GASTRIC AND DUODENAL ULCERS CAUSED BY NSAIDS 43 FOR THE PREVENTION OF GASTRIC AND DUODENAL ULCERS CAUSED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS ALI S. TAHA, PH.D., NICHOLAS HUDSON,
More informationD DAVID PUBLISHING. 1. Introduction. Maher Mbarki 1, Helen Sklyarova 1, Krystyna Aksentiychuk 1, Ihor Tumak 2 and Eugene Sklyarov 1
Journal of Pharmacy and Pharmacology (2016) 32-36 doi: 10.17265/232-2150/2016.0.011 D DAVID PUBLISHING Plasma Levels of Leukotriene B and Prostaglandin E2 Correlation with Endoscopic Changes after NSAID
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationRole of Helicobacter pylori in ulcer healing and
22 Departments of Gastroenterology G Bianchi Porro F Parente V Imbesi and Rheumatology F Montrone I Caruso L Sacco University Hospital, Milan, Italy Correspondence to: Professor G Bianchi Porro, Gastrointestinal
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationAssessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology36-5251Blackwell Publishing 23? 23562146155Original ArticleNSAID damage in the human gastrointestinal tractm. W. James & C. J.
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationA HISTOLOGICAL STUDY OF THE EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) ON THE GASTRIC AND DUODENAL MUCOSA
A HISTOLOGICAL STUDY OF THE EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) ON THE GASTRIC AND DUODENAL MUCOSA Abstract Pages with reference to book, From 287 To 290 Naheed Moghal, N.A. Jafarey
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationNon-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract
Journal of Gastroenterology and Hepatology (2000) 15, G58 G68 WORKING PARTY REPORT: NSAID Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract JJY SUNG,* RI RUSSELL, 1 N YEOMANS,
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationQuantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use
Pain 85 (2000) 169±182 www.elsevier.nl/locate/pain Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Martin R. TrameÁr a, *,
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationAn evaluation of whole blood testing for Helicobacter pylori in general practice
Aliment Pharmacol Ther 1998; 12: 641±645. An evaluation of whole blood testing for Helicobacter pylori in general practice N. J. TALLEY, J. R. LAMBERT*, S. HOWELL, H. H.-X. XIA, S. K. LIN* & L. AGREUS
More informationDouble-blind comparison of efficacy and
Annals of the Rheumatic Diseases 1993; 52: 881-885 881 Searle, Box 5110, Chicago, Ill 60680-5110, USA J A Melo Gomes S H Roth J Zeeh G A W Bruyn E M Woods G S Geis Correspondence to: Dr G S Geis Accepted
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in
More informationThink Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks
NEWS AND PERSPECTIVES Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks Jyh-Ming Liou, 1,2 Ming-Shiang Wu, 1 * Jaw-Town Lin 1,3 Nonsteroidal
More informationPrevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best?
Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best? Shaden Salamae MD a, Meir Antopolsky MD a, Ruth Stalnikowicz MD a * Department of Emergency Medicine, Hadassah University
More informationETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh.
ETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh. Taralunga² 1.CLINICAL EMERGENCY COUNTY HOSPITAL CONSTANŢA, GERIATRICS DEPARTAMENT
More informationPREVENTING UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH HELICOBACTER PYLORI INFECTION
PREVENTING RECURRENT UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH HELICOBACTER PYLORI INFECTION WHO ARE TAKING LOW-DOSE ASPIRIN OR NAPROXEN FRANCIS K.L. CHAN, M.D., S.C. SYDNEY CHUNG, M.D., BING YEE
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationPATTERN OF USE OF GASTROPROTECTIVE AGENTS ALONG WITH THE ANTI INFLAMMATORY AND ANALGESICS DRUGS
PATTERN OF USE OF GASTROPROTECTIVE AGENTS ALONG WITH THE ANTI INFLAMMATORY AND ANALGESICS DRUGS K. B. Sanalkumar 1, K. T. Shenoy 2, K. Arun 3, Hema Ilavarasi K. M 4, Venugopalan P.G 5, Leena K. B 6 1Additional
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationLow-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight ph study
Aliment Pharmacol Ther 1998; 12: 469±474. Low-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight ph study T. G. REILLY*, C. E. GRIMLEY*, B. USSELMANN*, J. COTTRELL,S.G.MANN,S.RASKINà&
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationINTRODUCTION ORIGINAL ARTICLE. Sang Gyun Kim 1, Nayoung Kim 2, Sung Kwan Shin 3, In Kyung Sung 4, Su Jin Hong 5 and Hyo-Jin Park 3
ORIGINAL ARTICLE Clin Endosc 2017;50:179-184 https://doi.org/10.5946/ce.2016.031 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant
More informationM Frezza, N Gorji, M Melato. The chronic use of non-steroidal antiinflammatory
J Clin Pathol 2001;54:521 525 521 Unit of Gastroenterology, General Hospital, I-34149 Trieste, Italy M Frezza Department of Pathological Anatomy, General Hospital and University of Trieste N Gorji M Melato
More informationEfficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
Alimentary Pharmacology & Therapeutics Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs C. J. HAWKEY*,
More informationThe management of arthritis and chronic pain syndromes
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1337 1345 Impact of Adherence to Concomitant Gastroprotective Therapy on Nonsteroidal-Related Gastroduodenal Ulcer Complications JAY L. GOLDSTEIN,* KIMBERLY
More informationNonsteroidal anti-inflammatory drugs (NSAIDs),
GASTROENTEROLOGY 2001;120:594 606 Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient LOREN LAINE University of Southern California School of Medicine, Los Angeles, California
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationA. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.
Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine
More informationProceedings of the First Hong Kong (Asia PacFfic) Medical Informatics Conference
HK Proceedings of the First Hong Kong (Asia PacFfic) Medical Informatics Conference Hong Kong Polytechnid 6-18 November 1990 Edited by ANTHONY J HEDLEY Department of Community Medicine University of Hong
More informationABSTRACT Background Suppressing acid secretion is thought
OMEPRAZOLE VS. RANITIDINE FOR ULCERS ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS A COMPARISON OF OMEPRAZOLE WITH RANITIDINE FOR ULCERS ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS NEVILLE
More informationModelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M
Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic
More informationPreventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity
Gut and Liver, Vol. 8, No. 4, July 2014, pp. 371-379 ORiginal Article Preventive Efficacy and Safety of in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity Jeong Ho Kim*,a, Soo-Heon Park*,
More informationPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin
Aliment Pharmacol Ther 2005; 22: 795 801. doi: 10.1111/j.1365-2036.2005.02649.x Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin N. D. YEOMANS*,
More informationA Study of the Correlation between Endoscopic and Histological Diagnoses in Gastroduodenitis
000-9 70/8 7/80S-0749 THE AMERICAN JOIIRNAE. OF GAsrR()E.NrER 1987 by Am. Coll.ofGastroenterology Vo!.8. No. 8, 1487 Printed in U.S.A. A Study of the Correlation between Endoscopic
More informationGastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses
The Journal of International Medical Research 2002; 30: 301 308 Gastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses P RAMPAL 1, N MOORE 2, E VAN GANSE
More informationSUMMARY INTRODUCTION. Accepted for publication 22 January 2003
Aliment Pharmacol Ther 23; 17: 1535 1543. doi: 1.146/j.1365-236.23.1587.x Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationPeptic ulcer and non-steroidal anti-inflammatory
Gut, 1986, 27, 929-933 Peptic ulcer and non-steroidal anti-inflammatory agents J M DUGGAN, ANNETTE J DOBSON, H JOHNSON, AND P FAHEY From the Gastroenterology Unit, Royal Newcastle Hospital, and Faculty
More informationSt. Mary s Hospital, The Catholic University of Korea, Seoul , Korea 2. Hanyang University Hospital, Hanyang University, Seoul , Korea 3
Original Article J. Clin. Biochem. Nutr., 40, 148 155, March 2007 Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled
More informationManagement of nonsteroidal anti-inflammatory drug
BYRON CRYER, MD ABSTRACT OBJECTIVE: To describe risk factors and review appropriate management strategies for patients who experience nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal
More informationCyclooxygenase-2 Expression in Gastric Antral Mucosa Before and After Eradication of Helicobacter pylori Infection
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 94, No. 5, 1999 1999 by Am. Coll. of Gastroenterology ISSN 0002-9270/99/$20.00 Published by Elsevier Science Inc. PII S0002-9270(99)00126-4 Cyclooxygenase-2
More informationOSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS DICLOFENAC
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-416 OSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationDyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac
Aliment Pharmacol Ther 2002; 16: 819 827. Dyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac J. L. GOLDSTEIN*, G. M. EISEN, T. A. BURKEà, B. M. PEÑA, J. LEFKOWITH
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationOmeprazole Ameliorates Aspirin-Induced Gastroduodenal Injury
Digestive Diseases and Sciences, Vol. 39, No. 1 (January 1994), pp. 97-103 Omeprazole Ameliorates Aspirin-Induced Gastroduodenal Injury JAMES M. SCHEIMAN, MD, ELIZABETH M. BEHLER, RN, KATHRYN M. LOEFFLER,
More informationMeta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials
Alimentary Pharmacology & Therapeutics Meta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials Y.-H. YUAN*,, C. WANG*, Y. YUAN*
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationHow do NSAIDs cause ulcer disease?
BaillieÁ re's Clinical Gastroenterology Vol. 14, No. 1, pp. 147±159, 2000 doi:10.1053/bega.1999.0065, available online at http://www.idealibrary.com on 11 How do NSAIDs cause ulcer disease? John L. Wallace
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationEpidemiology of Peptic Ulcer Disease
Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active
More informationEffect of glutamine on the intestinal permeability changes induced by indomethacin in humans
Aliment Pharmacol Ther 1999; 13: 679±685. Effect of glutamine on the intestinal permeability changes induced by indomethacin in humans E. DEN HOND, M. PEETERS, M. HIELE, V. BULTEEL, Y. GHOOS & P. RUTGEERTS
More informationWhich peptic ulcer patients bleed?
Gut, 1988, 29, 70-74 Which peptic ulcer patients bleed? K MATTHEWSON, S PUGH, AND T C NORTHFIELD From the Gastroenterology Units, St James Hospital, Balham and University College Hospital, London SUMMARY
More informationCelecoxib: the need to know for safe prescribing
medicine indications pain management rheumatology Celecoxib: the need to know for safe prescribing Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor that has been fully subsidised without restriction,
More informationLansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice
Aliment pharmacol Ther 1997: 11: 541±546. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice R. H. JONES & G. BAXTER* Department of General
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More informationA PLACEBO CONTROLLED TRIAL OF BISMUTH SALICYLATE IN HELICOBACTER PYLORI ASSOCIATED GASTRITIS
A PLACEBO CONTROLLED TRIAL OF BISMUTH SALICYLATE IN HELICOBACTER PYLORI ASSOCIATED GASTRITIS Pages with reference to book, From 154 To 156 Javed Iqbal Kazi, Naeem Aon Jafarey, Syed Mahmood Alam ( Department
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationOMEPRAZOLE VS. MISOPROSTOL FOR ULCERS ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS
OMEPRAZOLE VS. MISOPROSTOL FOR ULCERS ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS OMEPRAZOLE COMPARED WITH MISOPROSTOL FOR ULCERS ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS CHRISTOPHER
More informationEvidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1156 1163 REVIEW Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm ANDREW MOORE,* INGVAR
More informationThe New England Journal of Medicine
VERSUS AND IN REDUCING THE RISK OF RECURRENT ULCER BLEEDING IN PATIENTS WITH ARTHRITIS FRANCIS K.L. CHAN, M.D., LAWRENCE C.T. HUNG, M.D., BING Y. SUEN, R.N., JUSTIN C.Y. WU, M.D., KENNETH C. LEE, PH.D.,
More informationDuodenal Ulcer / Duodenitis
Duodenal Ulcer / Duodenitis Endoscopy Department Patient information leaflet You will only be given this leaflet if you have been diagnosed with duodenitis and/or a duodenal ulcer. The information below
More informationAbdominal Pain in a Young Aviator
Abdominal Pain in a Young Aviator Calen N. Wherry, MD, MPH Maj, USAF, MC, FS Peter A. Baldwin, MD, MBA, MPH Capt, USAF, MC, FS USAF School of Aerospace Medicine WPAFB, OH RAM 2013 Distribution A: Approved
More informationReview article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication
Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 66 70. Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication G. HOLTMANN* & C. W. HOWDEN
More informationKEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.
INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY Karunamoorthy Rajachidambaram 1, Dinkaran Kaarthesan
More informationRimoxen. Rimoxen! "The Gastro and Cardio friendly anti-inflammatory ingredient"
Rimoxen A Botanical Anti-Inflammatory COX-2 Selective Ingredient Question: How doses Rimoxen compare to the prescription COX-2 inhibitors (Vioxx and Celebrex) and the OTC NSAID pain relievers such as aspirin
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More information